Tobi 2015 report

Tobi 2015 report
Tobi 2015 report
Posted in

[sf_modal header=”Sample Report Request” btn_colour=”lightgrey” btn_type=”standard” extraclass=”280-width” btn_size=”small” btn_text=” REQUEST A FREE SAMPLE”]

    Name (required)

    Company (required)

    Email Address (required)

    [/sf_modal]

    [sf_button colour=”lightgrey” link=/reports/ target=”_self”  dropshadow=”no” extraclass=”set_t_width”]FIND ANOTHER REPORT[/sf_button]

    Tobi 2015 U.S. PROMOTIONAL AUDIT REPORT

    Published July 2016 • 27 Pages

    The 5 Key Questions Addressed by this Report:

    • How many physicians were reached by Tobi through personal promotion in 2015 and how does this compare to its peer set in the Cystic Fibrosis market?
    • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
    • How does Novartis’s depth of coverage vary within key specialties (e.g., Pediatric Medicine, Pulmonology, Internal Medicine, Allergy/Immunology, and Critical Care Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
    • How often are physicians receiving paid meals for Tobi throughout the year (e.g., monthly, quarterly, annually)?
    • Who were the most detailed prescribers and top paid speakers/consultants for Tobi in 2015?

    Data Sources and Methodology:

    • MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
    • Over 300 paid interactions across 200 physicians made on behalf of Tobi were carefully examined to support our analysis. In addition, interaction data from 5 peer products (e.g. Bethkis, Cayston, Kalydeco, Orkambi, and Pulmozyme) was leveraged to provide benchmarking and market insights.